...
首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies
【24h】

An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies

机译:一种改进的带有荧光检测的HPLC分析法,用于测定多潘立酮和三种主要代谢物,用于体外药物代谢研究

获取原文
获取原文并翻译 | 示例

摘要

Domperidone is currently used in Canada and Europe for the treatment of intestinal motility disorders as well as for its antiemefic properties. Recent drug metabolism studies have indicated that domperidone is a substrate of different subtypes of CYP3A family and consequently, the drug requires complete characterization of its metabolism for the identification of major drug-drug interactions. Therefore, the purpose of our studies was to develop a simple, sensitive and rapid HPLC assay for the determination of domperidone and its major metabolites. This assay had to be suitable for the conduct of in vitro drug metabolism study with human liver microsomes. Baseline resolution of internal standard, domperidone and three of its major metabolites was achieved in a run time of less than 15 min using an Ultrasphere ODS column (250 mm x 4.6 mm x 5 mu M) and a mobile phase consisting of disodium citrate buffer (10 mM, pH 3.4): methanol: acetonitrile:trietylamine, 54.6:34.7:9.9:0.8 at a flow rate of 1.0 mL/min. Chromatographic separation was executed at room temperature. Quantification was performed by tandem fluorescence (excitation; lambda = 282 nm and emission lambda = 328 nm) and ultraviolet detectors (lambda = 254 nm for the quantification of encainide, internal standard). Calibration curves were constructed and showed linearity in the range of 0.1-20 mu mol/L and 10-250 mu mol/L. Intra- and interday coefficients of variation were less than 8% and 11%, respectively. Mean accuracy was 100.5 +/- 9.9% and limit of quantification was established at 0.06 mu mol/L for domperidone and its metabolites. The assay allows estimation of enzymatic parameters (K-m and V-max) of domperidone for the formation of its various metabolites and sensitivity is sufficient for the conduct of inhibition studies with potent CYP3A inhibitors. (c) 2007 Elsevier B.V. All rights reserved.
机译:多潘立酮目前在加拿大和欧洲用于治疗肠动力性疾病及其抗肠胃功能。最近的药物代谢研究表明,多潘立酮是CYP3A家族不同亚型的底物,因此,该药物需要对其代谢进行完整表征,以鉴定主要的药物-药物相互作用。因此,我们的研究目的是开发一种简单,灵敏,快速的HPLC测定多潘立酮及其主要代谢产物的方法。该测定必须适合于用人肝微粒体进行体外药物代谢研究。使用Ultrasphere ODS色谱柱(250 mm x 4.6 mm x 5μM)和由柠檬酸二钠缓冲液组成的流动相,在不到15分钟的运行时间内即可实现内标,多潘立酮及其三种主要代谢物的基线分离10 mM,pH 3.4):甲醇:乙腈:三乙胺,54.6:34.7:9.9:0.8,流速为1.0 mL / min。在室温下进行色谱分离。通过串联荧光(激发;λ= 282 nm,发射λ= 328 nm)和紫外线检测器(lamcada = 254 nm,用于对恩卡因的定量,内标)进行定量。建立了校准曲线,并显示了在0.1-20μmol/ L和10-250μmol/ L范围内的线性。盘中和盘中的变异系数分别小于8%和11%。平均准确度为100.5 +/- 9.9%,对多潘立酮及其代谢物的定量极限为0.06μmol / L。该测定法可估计多潘立酮用于形成其各种代谢产物的酶学参数(K-m和V-max),灵敏度足以进行有效的CYP3A抑制剂的抑制研究。 (c)2007 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号